Abstract
One of the most abundant proteins expressed in the brain, 14-3-3 comprises about 1% of the brain’s total soluble proteins. The 14-3-3 isoforms bind to specific phosphoserine- and phosphothreonine-containing motifs found on a variety of signaling proteins (kinases and transcription factors, among others) to regulate a wide array of cellular processes including cell cycling, apoptosis, and autophagy. Previously, we described the expression of different 14-3-3 isoforms in the rat frontal cortex and reported their downregulation in a rodent model of neurodegeneration. To further investigate possible roles of 14-3-3 proteins in neurodegeneration, the present study examined different 14-3-3 isoforms in the frontal cortex of postmortem Alzheimer’s disease (AD) patients and control subjects. Among the different 14-3-3 isoforms in the human frontal cortex, the relative abundance of expression is in the following order: 14-3-3-eta > tau > sigma > gamma > epsilon > zeta/delta > beta/alpha. These relative abundance levels of different 14-3-3 isoforms in human frontal cortex closely resemble those in rat frontal cortex, suggesting a conserved expression pattern of different 14-3-3 isoforms in mammalian species. In the AD samples, there was a significant decrease in total 14-3-3 levels and the 14-3-3-eta and 14-3-3-gamma isoforms, while no significant difference in the expression level of other 14-3-3 isoforms between AD and control brains was detected. Together, these results demonstrate an abundance of several 14-3-3 isoforms in the frontal cortex and that a downregulation of total 14-3-3 protein levels and specific 14-3-3 isoforms is associated with neurodegeneration. Given the known function of 14-3-3 proteins as inhibitors of apoptosis, the present results suggest that 14-3-3 proteins may play an important role in neurodegeneration and deserve further investigations into AD and other neurodegenerative disorders.
Similar content being viewed by others
References
Moore BW, Perez VJ (1967) Specific acidic proteins of the nervous system. In: Carlson FD (ed) Physiological and biochemical aspects of nervous integration. Prentice-Hall, Englewood Cliffs, pp. 343–359
Fu H, Subramanian RR, Masters SC (2000) 14-3-3 proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol 40:617–647. https://doi.org/10.1146/annurev.pharmtox.40.1.617
Berg D, Holzmann C, Riess O (2003) 14-3-3 proteins in the nervous system. Nat Rev Neurosci 4:752–762. https://doi.org/10.1038/nrn1197
Rosenquist M (2003) 14-3-3 proteins in apoptosis. Braz J Med Biol Res 36:403–408
Aitken A (2006) 14-3-3 proteins: a historic overview. Semin Cancer Biol 16:162–172
Gardino AK, Yaffe MB (2011) 14-3-3 proteins as signaling integration points for cell cycle control and apoptosis. Semin Cell Dev Biol 22:688–695. https://doi.org/10.1016/j.semcdb.2011.09.008
Pozuelo-Rubio M (2012) 14-3-3 proteins are regulators of autophagy. Cell 1:754–773. https://doi.org/10.3390/cells1040754
Steinacker P, Aitken A, Otto M (2011) 14-3-3 proteins in neurodegeneration. Semin Cell Dev Biol 22:696–704. https://doi.org/10.1016/j.semcdb.2011.08.005
Shimada T, Fournier AE, Yamagata K (2013) Neuroprotective function of 14-3-3 proteins in neurodegeneration. Biomed Res Int 2013:564534–564511. https://doi.org/10.1155/2013/564534
Aitken A, Howell S, Jones D, Madrazo J, Patel Y (1995) 14-3-3 alpha and delta are the phosphorylated forms of raf-activating 14-3-3 beta and zeta. In vivo stoichiometric phosphorylation in brain at a Ser-Pro-Glu-Lys MOTIF. J Biol Chem 270:5706–5709
Boston PF, Jackson P, Kynoch PA, Thompson RJ (1982) Purification, properties, and immunohistochemical localisation of human brain 14-3-3 protein. J Neurochem 38:1466–1474
Layfield R, Fergusson J, Aitken A, Lowe J, Landon M, Mayer J (1996) Neurofibrillary tangles of Alzheimer’s disease brains contain 14-3-3 proteins. Neurosci Lett 209:57–60
Hashiguchi M, Sobue K, Paudel HK (2000) 14-3-3zeta is an effector of tau protein phosphorylation. J Biol Chem 275:25247–25254. https://doi.org/10.1074/jbc.M003738200
Yuan Z, Agarwal-Mawal A, Paudel HK (2004) 14-3-3 binds to and mediates phosphorylation of microtubule-associated tau protein by Ser9-phosphorylated glycogen synthase kinase 3beta in the brain. J Biol Chem 279:26105–26114. https://doi.org/10.1074/jbc.M308298200
Qureshi HY, Li T, MacDonald R, Cho CM, Leclerc N, Paudel HK (2013) Interaction of 14-3-3ζ with microtubule-associated protein tau within Alzheimer’s disease neurofibrillary tangles. Biochemistry 52:6445–6455. https://doi.org/10.1021/bi400442d
Kawamoto Y, Akiguchi I, Nakamura S, Honjyo Y, Shibasaki H, Budka H (2002) 14-3-3 proteins in Lewy bodies in Parkinson disease and diffuse Lewy body disease brains. J Neuropathol Exp Neurol 61:245–253
Ubl A, Berg D, Holzmann C, Krüger R, Berger K, Arzberger T, Bornemann A, Riess O (2002) 14-3-3 protein is a component of Lewy bodies in Parkinson’s disease-mutation analysis and association studies of 14-3-3 eta. Brain Res Mol Brain Res 108:33–39
Berg D, Riess O, Bornemann A (2003) Specification of 14-3-3 proteins in Lewy bodies. Ann Neurol 54:135. https://doi.org/10.1002/ana.10621
Xu J, Kao SY, Lee FJ, Song W, Jin LW, Yankner BA (2002) Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med 8:600–606. https://doi.org/10.1038/nm0602-600
Plotegher N, Kumar D, Tessari I, Brucale M, Munari F, Tosatto L, Belluzzi E, Greggio E et al (2014) The chaperone-like protein 14-3-3η interacts with human α-synuclein aggregation intermediates rerouting the amyloidogenic pathway and reducing α-synuclein cellular toxicity. Hum Mol Genet 23:5615–5629. https://doi.org/10.1093/hmg/ddu275
Halskau Ø Jr, Ying M, Baumann A, Kleppe R, Rodriguez-Larrea D, Almås B, Haavik J, Martinez A (2009) Three-way interaction between 14-3-3 proteins, the N-terminal region of tyrosine hydroxylase, and negatively charged membranes. J Biol Chem 284:32758–32769. https://doi.org/10.1074/jbc.M109.027706
Wang J, Lou H, Pedersen CJ, Smith AD, Perez RG (2009) 14-3-3zeta contributes to tyrosine hydroxylase activity in MN9D cells: localization of dopamine regulatory proteins to mitochondria. J Biol Chem 284:14011–14019. https://doi.org/10.1074/jbc.M901310200
Sato S, Chiba T, Sakata E, Kato K, Mizuno Y, Hattori N, Tanaka K (2006) 14-3-3eta is a novel regulator of parkin ubiquitin ligase. EMBO J 25:211–221. https://doi.org/10.1038/sj.emboj.7600774
Pirim I (1998) Ischemic rat brains contain immunoreactivity of 14-3-3 proteins. Int J Neurosci 95:101–106
Baxter HC, Liu WG, Forster JL, Aitken A, Fraser JR (2002) Immunolocalisation of 14-3-3 isoforms in normal and scrapie-infected murine brain. Neuroscience 109:5–14
van der Brug MP, Goodenough S, Wilce P (2002) Kainic acid induces 14-3-3 zeta expression in distinct regions of rat brain. Brain Res 956:110–115
Schindler CK, Shinoda S, Simon RP, Henshall DC (2004) Subcellular distribution of Bcl-2 family proteins and 14-3-3 within the hippocampus during seizure-induced neuronal death in the rat. Neurosci Lett 356:163–166. https://doi.org/10.1016/j.neulet.2003.11.048
Hu X, Rea HC, Wiktorowicz JE, Perez-Polo JR (2006) Proteomic analysis of hypoxia/ischemia-induced alteration of cortical development and dopamine neurotransmission in neonatal rat. J Proteome Res 5:2396–2404. https://doi.org/10.1021/pr060209x
Kawamoto Y, Akiguchi I, Tomimoto H, Shirakashi Y, Honjo Y, Budka H (2006) Upregulated expression of 14-3-3 proteins in astrocytes from human cerebrovascular ischemic lesions. Stroke 37:830–835. https://doi.org/10.1161/01.STR.0000202587.63936.37
Schindler CK, Heverin M, Henshall DC (2006) Isoform- and subcellular fraction-specific differences in hippocampal 14-3-3 levels following experimentally evoked seizures and in human temporal lobe epilepsy. J Neurochem 99:561–569. https://doi.org/10.1111/j.1471-4159.2006.04153.x
Slone SR, Lavalley N, McFerrin M, Wang B, Yacoubian TA (2015) Increased 14-3-3 phosphorylation observed in Parkinson’s disease reduces neuroprotective potential of 14-3-3 proteins. Neurobiol Dis 79:1–13. https://doi.org/10.1016/j.nbd.2015.02.032
Smani D, Sarkar S, Raymick J, Kanungo J, Paule MG, Gu Q (2018) Down-regulation of 14-3-3 proteins in a kainic acid-induced neurotoxicity model. Mol Neurobiol 55:122–129. https://doi.org/10.1007/s12035-017-0724-y
Masters SC, Yang H, Datta SR, Greenberg ME, Fu H (2001) 14-3-3 inhibits bad-induced cell death through interaction with serine-136. Mol Pharmacol 60:1325–1331
Murphy N, Bonner HP, Ward MW, Murphy BM, Prehn JH, Henshall DC (2008) Depletion of 14-3-3 zeta elicits endoplasmic reticulum stress and cell death, and increases vulnerability to kainate-induced injury in mouse hippocampal cultures. J Neurochem 106:978–988. https://doi.org/10.1111/j.1471-4159.2008.05447.x
Yacoubian TA, Slone SR, Harrington AJ, Hamamichi S, Schieltz JM, Caldwell KA, Caldwell GA, Standaert DG (2010) Differential neuroprotective effects of 14-3-3 proteins in models of Parkinson’s disease. Cell Death Dis 1:e2. https://doi.org/10.1038/cddis.2009.4
Slone SR, Lesort M, Yacoubian TA (2011) 14-3-3theta protects against neurotoxicity in a cellular Parkinson’s disease model through inhibition of the apoptotic factor Bax. PLoS One 6:e21720. https://doi.org/10.1371/journal.pone.0021720
Wu JS, Cheung WM, Tsai YS, Chen YT, Fong WH, Tsai HD, Chen YC, Liou JY et al (2009) Ligand-activated peroxisome proliferator-activated receptor-gamma protects against ischemic cerebral infarction and neuronal apoptosis by 14-3-3 epsilon upregulation. Circulation 119:1124–1134. https://doi.org/10.1161/CIRCULATIONAHA.108.812537
Zhu Y, Bu Q, Liu X, Hu W, Wang Y (2014) Neuroprotective effect of TAT-14-3-3ε fusion protein against cerebral ischemia/reperfusion injury in rats. PLoS One 9:e93334. https://doi.org/10.1371/journal.pone.0093334
Ding H, Underwood R, Lavalley N, Yacoubian TA (2015) 14-3-3 inhibition promotes dopaminergic neuron loss and 14-3-3θ overexpression promotes recovery in the MPTP mouse model of Parkinson's disease. Neuroscience 307:73–82. https://doi.org/10.1016/j.neuroscience.2015.08.042
Mazure CM, Swendsen J (2016) Sex differences in Alzheimer’s disease and other dementias. Lancet Neurol 15:451–452. https://doi.org/10.1016/S1474-4422(16)00067-3
Lu E, Sarkar S, Raymick J, Paule MG, Gu Q (2018) Decreased Mcl-1 protein level in the striatum of a Parkinson’s disease animal model. Brain Res 1678:432–439. https://doi.org/10.1016/j.brainres.2017.11.014
Fountoulakis M, Cairns N, Lubec G (1999) Increased levels of 14-3-3 gamma and epsilon proteins in brain of patients with Alzheimer’s disease and Down syndrome. J Neural Transm Suppl 57:323–335
MacKay RK, Colson NJ, Dodd PR, Lewohl JM (2011) Differential expression of 14-3-3 isoforms in human alcoholic brain. Alcohol Clin Exp Res 35:1041–1049. https://doi.org/10.1111/j.1530-0277.2011.01436.x
Watanabe M, Isobe T, Ichimura T, Kuwano R, Takahashi Y, Kondo H, Inoue Y (1994) Molecular cloning of rat cDNAs for the zeta and theta subtypes of 14-3-3 protein and differential distributions of their mRNAs in the brain. Brain Res Mol Brain Res 25:113–121
Umahara T, Uchihara T, Nakamura A, Iwamoto T (2011) Differential expression of 14-3-3 protein isoforms in developing rat hippocampus, cortex, rostral migratory stream, olfactory bulb, and white matter. Brain Res 1410:1–11. https://doi.org/10.1016/j.brainres.2011.06.036
Brennan GP, Jimenez-Mateos EM, McKiernan RC, Engel T, Tzivion G, Henshall DC (2013) Transgenic overexpression of 14-3-3 zeta protects hippocampus against endoplasmic reticulum stress and status epilepticus in vivo. PLoS One 8:e54491. https://doi.org/10.1371/journal.pone.0054491
Nomura M, Shimizu S, Sugiyama T, Narita M, Ito T, Matsuda H, Tsujimoto Y (2003) 14-3-3 interacts directly with and negatively regulates pro-apoptotic Bax. J Biol Chem 278:2058–2065. https://doi.org/10.1074/jbc.M207880200
Lundquist JJ, Dudek SM (2006) Differential activation of extracellular signal-regulated kinase 1 and a related complex in neuronal nuclei. Brain Cell Biol 35:267–281. https://doi.org/10.1007/s11068-008-9018-7
Vallee RB (1986) Reversible assembly purification of microtubules without assembly-promoting agents and further purification of tubulin, microtubule-associated proteins, and MAP fragments. Methods Enzymol 134:89–104
Goedert M (1993) Tau protein and the neurofibrillary pathology of Alzheimer’s disease. Trends Neurosci 16:460–465
Sadik G, Tanaka T, Kato K, Yanagi K, Kudo T, Takeda M (2009) Differential interaction and aggregation of 3-repeat and 4-repeat tau isoforms with 14-3-3zeta protein. Biochem Biophys Res Commun 383:37–41. https://doi.org/10.1016/j.bbrc.2009.03.107
Acknowledgments
We thank the University of Kentucky Alzheimer’s Disease Center Tissue Bank, University of Maryland Brain and Tissue Bank, University of Miami Brain Endowment Bank for the postmortem human tissue samples, and the anonymous donors. The University of Kentucky Alzheimer’s Disease Center Tissue Bank is supported by NIH (NIA P30 AG028383).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no competing interests.
Disclaimer
The information in these materials is not a formal dissemination of information by FDA and does not represent agency position or policy.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Gu, Q., Cuevas, E., Raymick, J. et al. Downregulation of 14-3-3 Proteins in Alzheimer’s Disease. Mol Neurobiol 57, 32–40 (2020). https://doi.org/10.1007/s12035-019-01754-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12035-019-01754-y